Search or
𝛼SK
𝛼SKbullish
Eisai Co Ltd (4523 JP): Impressive 1Q Result; Subcutaneous Leqembi Is Key for Future Growth
473 Views08 Aug 2025 08:30
Eisai reported strong Q1FY26 result with 55% increase in operating profit. Despite negative Fx impact, revenue grew 7%. Leqembi maintained sequential progress, amid upcoming new dosing approval.
What is covered in the Full Insight:
- Introduction
- Q1FY26 Performance
- Leqembi Growth Prospects
- Lenvima Sales Analysis
- Conclusion and Forward Outlook
Boomeranged on Mon, 1 Sep 2025 13:55
Eisai gets FDA nod for once weekly Leqembi subcutaneous autoinjector for maintenance dosing. The introduction of easy-to-use SC-AI will allow for administration at home, providing a new expanded treatment option so patients can benefit from continuous treatment. Moreover, SC-AI is expected to help lower overall medical costs associated with intravenous infusion.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Eisai Co Ltd (4523 JP): Label Expansion Drives Leqembi Ahead; Competitive Landscape Turns Favorable27 Nov 2025
- Eisai Co Ltd (4523 JP): Leqembi at a Growth Juncture as New Markets Open Up; Margins Under Pressure19 May 2025
- Eisai (4523 JP): 3L Drive 9MFY25 Result; FY25 Guidance Reaffirmed; Leqembi at an Inflection Point08 Mar 2025
- Eisai Co Ltd (4523 JP): Mixed H1FY25 Performance; Guidance Reaffirmed; Leqembi Struggle Continues21 Nov 2024
x